Our recent findings indicate that ETAR-AA seropositivity is linked to no-reflow in patients with STEMI, and both ETAR-AAs and AT1R-AAs elevate the risk of adverse left ventricular remodeling after myocardial infarction (12, 13). This evidence concerns the gene AGTR1 and myocardial infarction.